Brodalumab

Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight

Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis

Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Brodalumab in the Treatment of Immune-Related Adverse Events

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab

Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa

A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen

Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease

Long-term Safety Study of Brodalumab in Adults With Crohn's Disease

Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate

Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid Arthritis

Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies

Brodalumab in Palmoplantar Psoriasis

An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab